JJ
J&J expects consent decree to extend through ‘most of 2013’
July 30, 2012Manufacturing and Production FDA, J&J, JJ, McNeil, OTC, recall
Johnson & Johnson has said it expects the production capacity issues affecting two plants covered by a consent decree with …
New J&J chief still struggling with scandals
July 18, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Risperdal, Weldon, Xarelto, Zytiga
Johnson & Johnson has just released its Q2 figures showing sales fell back in the second quarter, a 3.5% growth …
Janssen submits tuberculosis pill to FDA
July 4, 2012Research and Development, Sales and Marketing Bedaquiline, FDA, J&J, JJ, Janssen, tuberculosis
Janssen has submitted its investigational tuberculosis pill bedaquiline for review by the FDA. The firm is seeking a licence for …
FDA rejects licence extension for Xarelto
June 26, 2012Sales and Marketing ACS, Bayer, FDA, J&J, JJ, Pradaxa, Xarelto
The FDA has set a Complete Response Letter to Bayer and J&J over its blood thinner Xarelto. The firms, which …
J&J fined after ‘lying to patients for profit’
April 16, 2012Medical Communications, Sales and Marketing J&J, JJ, Janssen, Risperdal, US
A US judge has slapped a $1.19 billion fine on Johnson & Johnson after it was found to be downplaying …
J&J unveils plans to boost Doxil supplies
April 10, 2012Manufacturing and Production Ben Venue, Doxil, J&J, JJ, drug shortages
Johnson & Johnson is planning to transfer filling and packaging of Doxil to another supplier in an attempt to alleviate …
Synthes plant cited in FDA warning letter
March 8, 2012Manufacturing and Production FDA, J&J, JJ, Synthes, manufacturing
The US FDA has sent a warning letter to surgical equipment manufacturer Synthes upbraiding it for deficiencies at a manufacturing …
Alex Gorsky named new chief executive of J&J
February 22, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Janssen, Weldon
Johnson & Johnson has named Alex Gorsky as its new chief executive, effective from 26 April. Gorsky was also nominated …
J&J to pay $1 billion for Risperdal charges
January 9, 2012Sales and Marketing J&J, JJ, Janssen, Risperdal
Johnson & Johnson will pay more than $1 billion in the US to resolve a civil investigation into the marketing …
Janssen sets up new mental health social networking site
November 28, 2011Medical Communications J&J, JJ, Janssen, NHS
Janssen and the NHS Confederation have established a new mental health social networking site. The service, which will be free …
Doxil shortages exacerbated as Ben Venue shutters plant
November 22, 2011Manufacturing and Production Doxil, J&J, JJ, manufacturing and production
An acute shortage of Johnson & Johnson’s cancer drug Doxil (doxorubicin) in the US could get worse following a decision …
Xarelto succeeds in new study
November 14, 2011Sales and Marketing Bayer, FDA, J&J, JJ, Xarelto
In a new study J&J and Bayer’s blood thinner Xarelto reduced deaths in patients after a heart attack, which could …
Merck pulls out of J&J consumer venture
September 29, 2011Sales and Marketing J&J, JJ, Merc & Co, OTC
Merck & Co has exited a joint venture with J&J, selling its stake in the J&J/Merck Consumer Pharmaceuticals business to …
J&J’s latest recall put down to new factor
August 19, 2011Manufacturing and Production J&J, JJ, Tylenol, recalls
Yet another Johnson & Johnson recall has been announced, but this time the perpetrator doesn’t feature among the ‘usual suspects’. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
